ImmuPharma PLC - London-based drug discovery and development company - Posts no revenue for 2022, compared to £118,350 for 2021. Pretax loss narrows to £4.5 million from £8.9 million a year earlier, as operating loss reduces to £3.0 million from £6.6 million. Research and development expenditure is £2.0 million, down from £3.7 million in 2021. Chief Executive Officer Tim McCarthy says: ‘As a board, we remain focused on bringing our two key late stage clinical assets, Lupuzor for lupus and CIDP closer to the market.’

Current stock price: 2.70 pence each, down 6.4% on Thursday in London

12-month change: down 55%

Copyright 2023 Alliance News Ltd. All Rights Reserved.